[
  {
    "ts": null,
    "headline": "Should Value Investors Buy DaVita (DVA) Stock?",
    "summary": "Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.",
    "url": "https://finnhub.io/api/news?id=d1c7e97f2a0645770a8e86145db783314b535c302108d48b4df49dd137fa7da9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770302403,
      "headline": "Should Value Investors Buy DaVita (DVA) Stock?",
      "id": 138364774,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "DVA",
      "source": "Yahoo",
      "summary": "Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.",
      "url": "https://finnhub.io/api/news?id=d1c7e97f2a0645770a8e86145db783314b535c302108d48b4df49dd137fa7da9"
    }
  },
  {
    "ts": null,
    "headline": "DaVita Links IKC Profitability With Elara Home Care To Recast Growth",
    "summary": "DaVita (NYSE:DVA) reports its Integrated Kidney Care program reached its first profitable year. The company also announces a new partnership with Elara Caring to expand home-based kidney care services. DaVita, trading at $142.06, sits at an interesting point for investors following kidney care and value based care models. The stock is up 34.2% over the past week and 24.7% over the past month, with a 70.0% return over three years and 25.3% over five years, while showing a 19.7% decline over...",
    "url": "https://finnhub.io/api/news?id=84ed3448d3dcae737c402a554efac52c0e74f2fba90e23b265d76e5d33f3054f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770251057,
      "headline": "DaVita Links IKC Profitability With Elara Home Care To Recast Growth",
      "id": 138360130,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "DVA",
      "source": "Yahoo",
      "summary": "DaVita (NYSE:DVA) reports its Integrated Kidney Care program reached its first profitable year. The company also announces a new partnership with Elara Caring to expand home-based kidney care services. DaVita, trading at $142.06, sits at an interesting point for investors following kidney care and value based care models. The stock is up 34.2% over the past week and 24.7% over the past month, with a 70.0% return over three years and 25.3% over five years, while showing a 19.7% decline over...",
      "url": "https://finnhub.io/api/news?id=84ed3448d3dcae737c402a554efac52c0e74f2fba90e23b265d76e5d33f3054f"
    }
  }
]